Drug firm Jubilant Life Sciences today said its subsidiary has received final approval from the US health regulator for Amantadine Hydrochloride tablets, an anti-viral and anti-Parkinsons drug.
The approved drug, generic version of Symmetrel of Endo, is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. It is also indicated in the treatment of Parkinsonism and drug-induced extrapyramidal reactions.
"Jubilant Pharma Ltd, a material wholly owned subsidiary of the company, through one of its wholly owned subsidiaries, has received abbreviated new drug application (ANDA) final approval for Amantadine Hydrochloride tablets, 100 mg," Jubilant Life Sciences said in a BSE filing.
This is the ninth approval received by the company from the USFDA during the current financial year.
As on December 31, 2017, Jubilant Life Sciences had 86 ANDAs for oral solids filed in the US, of which 56 have been approved and 12 injectable filings, of which 10 had been approved, the filing added.
Shares of the company were trading 1.18 per cent down at Rs 956.95 on the BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)